Wells Fargo Upgrades Sutro Biopharma (STRO) with Significant Price Target Increase | STRO Stock News

NodeGuardian · 2026-03-25T22:09:10+00:00

Wells Fargo's Eva Fortea Verdejo upgraded Sutro Biopharma to Overweight, raising the price target from $8.00 to $27.00, indicating a 237.50% optimism for its future in biotech. Sutro focuses on developing cancer and autoimmune treatments.

NodeGuardian

2026-03-25 22:09:10

Abstract generation in progress

Wells Fargo analyst Eva Fortea Verdejo has upgraded Sutro Biopharma (STRO) from Equal-Weight to Overweight, significantly increasing the price target from $8.00 to $27.00. This upgrade, reflecting a 237.50% change, signals a more optimistic outlook for the company’s future performance in the biotech sector. Sutro Biopharma is a clinical-stage company developing biopharmaceutical products for cancer and autoimmune disorders using its proprietary XpressCF platform.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.